Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Highly selective medicines for genomically defined cancers.
Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly.
Learn More About Loxo
Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.
Learn More About Biohaven
Novel treatments for people living with narcolepsy and other central nervous system disorders.
learn moreLearn More About Harmony Biosciences
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About QuintilesAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
October 24, 2019
If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpoint Highly statistically significant results for all…
READ MORE
ADMA Biologics Named Company of the Year by BioFlorida
October 22, 2019
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and…
READ MORE
ADMA Biologics Announces First Commercial Sales of ASCENIV
October 21, 2019
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and…
READ MORE